Medicine Atlas

How Healing Is Practiced
Sign In
Text size
100%
Theme
Condition

Canavan disease

Endocrine Nutritional and Metabolic Diseases

Canavan disease is a rare and fatal autosomal recessive degenerative disease that causes progressive damage to nerve cells and loss of white matter in the brain, resulting from a deficiency of the enzyme aspartoacylase that leads to breakdown of the myelin insulating nerve fibers. Because it is autosomal recessive, a child has a 25 percent chance of being affected when both parents carry the defective gene. The severe form typically appears in early infancy, between three and six months old, with intellectual disability, loss of motor skills, feeding difficulties, abnormal muscle tone, poor head control and an enlarged head; advanced cases may involve paralysis, blindness or seizures, and this form typically causes death or life-threatening complications by age ten. A milder, later-onset variant exists with minimal developmental delay and little effect on lifespan. The disease predominantly affects people of Eastern European Jewish ancestry, among whom about one in 40 carries the gene.

Facts
Classification
Body System
Nervous System 1
ICD-10 Chapter
IV: Endocrine, Nutritional and Metabolic Diseases 2
Communicable or Non-communicable
Non-Communicable 1
Causative Agent
Causative Agent (category)
Genetic / Hereditary 1
First Described
1931 1
Sources
1. Canavan disease (Wikipedia)
  • lead sentence 1
    Canavan disease, or Canavan-Van Bogaert-Bertrand disease, is a rare and fatal autosomal recessive degenerative disease that causes progressive damage to nerve cells and loss of white matter in the brain.
  • Lead: disease category
    Canavan disease, or Canavan-Van Bogaert-Bertrand disease, is a rare and fatal autosomal recessive degenerative disease that causes progressive damage to nerve cells and loss of white matter in the brain.
  • Article text
    Canavan disease was first described in 1931 by Myrtelle Canavan.
View the Source
2. Wikidata: Canavan disease
Wikidata P494 (E75.2)View the Source
Comments (0)
No comments yet. Be the first to share a thought.
Reader Challenges (0)
No disputes yet. Spotted an error or a better source? Open the first one.